45 results about "Lactococcus garvieae" patented technology

The present invention relates to a pharmaceutical composition which includes naturally occurring, non-transgenic isolated bacteria from the group of Lactococcus and Acinetobacter or fragments thereof or mixtures thereof, to such a bacterium as a medicament for the prevention and / or treatment of allergic or chronic inflammatory disorders and to a process for producing this composition.

The invention is in the field of molecular biology, and relates to recombinant engineering and protein expression. More in particular, the invention relates to nucleic acids for recombinant expression of proteins comprising sequences derived from Lactococcus and useful as promoters. The invention further relates to vectors comprising the nucleic acids and host cells transformed therewith. The invention also covers the use of host cells comprising the nucleic acids or vectors for expressing heterologous or homologous proteins; and also for delivery, especially therapeutic delivery, of the said proteins to subjects.

The invention relates to a recombinant Lactococcus strain, with environmentally limited growth and viability. More particularly, it relates to a recombinant Lactococcus that can only survive in a medium, where well-defined medium compounds are present. A preferred embodiment is a Lactococcus that may only survive in a host organism, where such medium compounds are present, but cannot survive outside the host organism in the absence of such medium compounds.

The present invention relates to a Myoviridae bacteriophage Lac-GAP-1 that is isolated from the nature and can kill specifically Lactococcus garvieae cells, which has a genome represented by the nucleotide sequence of SEQ. ID. NO: 1 (Accession NO: KCTC 12686BP), and a method for preventing and treating the infections of Lactococcus garvieae using the composition comprising said bacteriophage as an active ingredient.

The present invention relates to a food composition for alleviating a hangover, the composition containing, as an active ingredient, at least one strain selected from Lactococcus chungangensis, Lactococcus fujiensis, Lactococcus lactis subsp. cremoris, Lactococcus lactis subsp. lactis, and Lactococcus raffinolactis or a culture liquid thereof. Specifically, a functional cream cheese was manufactured using five species of Lactococcus strains above having an ethanol and acetaldehyde degrading function, and this functional cream cheese is preferably used for a functional health food for alleviating a hangover, and, extensively, acetaldehyde, which is an ethanol degradation product, is degraded to minimize the accumulation of acetaldehyde, which is likely to cause cancer in the body. In addition, the functional cream cheese, which is a cheese starter for lowering a unit cost compared with cream cheeses in the market, can be differentiated from cream cheeses sold in the market.

To provide a microorganism and an ingredient thereof that contribute to prevention and treatment of immune diseases including allergy, autoimmune diseases and inflammatory bowel diseases (e.g., large-intestinal ulcer), a method of effectively selecting the microorganism, and a method of efficiently inducing immunoregulatory cells that play an important role on maintaining immunological homeostasis using the microorganism or the ingredient thereof. The present invention provides a Lactococcus and an ingredient thereof which induce production of IL-10 from mammalian dendritic or spleen cells, a method of obtaining the microorganism or the ingredient thereof by co-culturing a microorganism such as Lactococcus strains with mammalian dendritic or spleen cells to select a microbial cell having a high IL-10 production ability, a method of selecting the microorganism or the ingredient thereof by co-culturing an intestinal epithelial cell with a microorganism such as the lactic acid bacteria and selecting the cells on the basis of a caspase-1 activity and the ability of inducing the production of IL-18, and a food product or material and an animal feeding stuff or medical and pharmaceutical products which contain the lactic acid bacteria as an effective ingredient.

The invention relates to a recombinant Lactococcus strain, with environmentally limited growth and viability. More particularly, it relates to a recombinant Lactococcus that can only survive in a medium, where well-defined medium compounds are present. A preferred embodiment is a Lactococcus that may only survive in a host organism, where such medium compounds are present, but cannot survive outside the host organism in the absence of such medium compounds.

The invention provides sika deer coronet antibacterial peptides / proteins with antibacterial effect and applications thereof, including sika deer coronet micromolecular polypeptides, sika deer coronet collagen hydrolyzing peptides, and sika deer coronet micromolecular protein monomers. The peptides / proteins are subjected to inhibition ring tests so as to observe the inhibiting effect on Gram-negative bacteria, Gram-positive bacteria, and fungi; wherein the Gram-negative bacteria comprise enterobacter aerogenes, proteus mirabilis, pseudomonas aeruginosa, and escherichia coli. The Gram-positive bacteria comprise staphylococcus lentus, lactococcus garvieae, staphylococcus xylosus, bacillus subtilis, and staphylococcus intermedius. The fungi are candida albicans. Under the effect of various bacteriostatic agents, the enterobacter aerogenes, bacillus subtilis, escherichia coli, pseudomonas aeruginosa, staphylococcus intermedius, and staphylococcus xylosus are inhibited to a certain degree, and the candida albicans, lactococcus garvieae, proteus mirabilis, and staphylococcus lentus are not inhibited.

The present invention discloses novel isolated strains of lactic acid producing bacteria of the genera Lactobacillus and Pediococcus, and a method for isolation of such bacterial strains, having the ability to colonise and become established in a human vagina, even during menstrual discharge. Furthermore, a composition comprising the bacterial strains and a sanitary article comprising the bacterial strains, such as a tampon, for prophylaxis and / or treatment of infections of the urogenital tract, are described. The present invention also describes a method for prophylaxis and / or treatment of infections of the urogenital tract, wherein at least one of the bacterial strains is administered vaginally.

Provide a visceral fat reducing agent for reducing the diseases and conditions associated with the metabolic syndrome which represents a condition where various risk factors such as those for hypertension, hyperlipemia, glucose tolerance dysfunction, etc., have accumulated, or simply reducing an accumulation of visceral fat, wherein the effective ingredient of said visceral fat reducing agent includes fungus bodies of lactic bacteria, especially lactic bacteria belonging to the Lactobacillus sp. and Lactococcus sp. and / or cultures thereof, while also providing a beverage, food or feed containing said visceral fat reducing agent.

The present disclosure relates to genetic markers for discrimination and detection of bacteria causing Edwardsiellosis and Streptococcosis in fish, and a method for discriminating and detecting the bacteria using the same. A genetic marker for discrimination and / or detection of each of Edwardsiella tarda, Streptococcus iniae, Streptococcus parauberis and Lactococcus garvieae, which cause fish diseases, is selected and a peptide nucleic acid and a primer pair, which are specific for the genetic marker, are used to amplify and obtain melting curves having different fluorescences depending on bacterial species. Thus, bacteria that cause fish diseases can be discriminated and whether or not fish would be infected with the bacteria can be detected in a simple, rapid and accurate manner.

The invention relates to a Lactococcus garvieae LGHK2 and an application thereof. The strain is collected in the Guangdong Culture Collection Center on September 5, 2018, with the collection number ofGDMCC No. 60443, and the collection address of the 5th Floor, Building 59, Compound 100, Xianlie Middle Road, Guangzhou City, Guangdong Province. The Lactococcus garvieae LGHK2 has strong acid production capacity, and can be used for fermenting fresh shrimp shells, and the decalcification rate can reach 69.47-77.75 percent; when the Lactococcus garvieae LGHK2 is used for fermenting fresh shrimp heads, the pH value of the fermentation liquid can be as low as 3.3, the apparent hydrolysis degree can reach 40.74%, and the protein removal rate can reach 97.0%, so that the fermentation liquid has high-efficiency calcium and protein dissolving capability; and when the Lactococcus garvieae LGHK2 is applied to the fermentation treatment of shrimp wastes, the utilization rate of the shrimp wastes can be improved, and meanwhile, the environmental compatibility is better.

The present invention relates to a Myoviridae bacteriophage Lac-GAP-1 that is isolated from the nature and can kill specifically Lactococcus garvieae cells, which has a genome represented by the nucleotide sequence of SEQ ID NO: 1 (Accession NO: KCTC 12686BP), and a method for preventing and treating the infections of Lactococcus garvieae using the composition comprising said bacteriophage as an active ingredient.

A complete nutritional composition comprising Lactococcus strains or probiotic is provided for reducing the symptoms of allergies in different groups of patients such as allergies originating from food allergens in young children or infants and respiratory allergens in children, adults and household pets. Preferably the composition reduces symptoms of allergies (secondary prevention) while not significantly affecting sensitization (primary prevention). The composition comprises a probiotic of the genus Lactococcus.

The invention discloses a Lactococcus garsneri, a biological preservative and an application thereof. The Lactococcus garseri is named as Lactococcus garviea SY-1, and the preservation number is CGMCC No.9485. The biological antiseptic preservative contains the fermentation liquid of the Lactococcus gasseri. The fermented liquid of Lactococcus grisneri SY-1 of the present invention has strong antibacterial and antibacterial activities, especially mixed with Jerusalem artichoke leaf extract in a certain proportion and used synergistically, and has a good control effect on black spot of root crops such as yams , greatly reducing its incidence rate, prolonging its storage time, and also has a certain freshness preservation effect; the mixture of Lactococcus grisneri SY-1 fermentation liquid and Jerusalem artichoke leaf extract of the present invention has safety, high efficiency, non-toxicity, no residue, It has many advantages such as being edible, and has good economic and social value.